Novo Nordisk strikes deal with Septerna to develop obesity pills The deal, worth up to $2.2B, comes amid a race to produce next-generation treatments Manage alerts for this article Email this article

https://www.statnews.com/2025/05/14/novo-nordisk-septerna-wegovy-obesity-weight-loss-pills/?utm_campaign=breaking_news&utm_medium=email&_hsenc=p2ANqtz-8c1a-FyMrRthbovHHrMm94Dxgii_40WjvcNP6_bVxull8JDOO6wMRDfzfc_cv8KOiN3OOJYBUIXSFC5VdVQnNd9paP2Q&_hsmi=361803897&utm_content=361803897&utm_source=hs_email